Prices are updated after-hours

Nasdaq United states

FedNat Holding Company

FNHC | $0.2

(0.0% 1d) (0.0% 1m) (0.0% 1y) (-29.6% 2d) (-29.6% 3d) (0.0% 7d) (141.92% volume)
Earnings Calendar: 2022-10-24
Market Cap: $ 3,503,847
http://www.fednat.com
Sec Filling | Patents | 357 employees

(US) FedNat Holding Co. engages in providing the insurance services. It offers underwriting services to homeowners, personal automobile, commercial general liability, federal flood, and other lines of insurance. The company was founded by Edward J. Lawson and Michele V. Lawson in 1991 and is headquartered in Sunrise, FL.

insurance automobile food

add to watch list Paper trade email alert is off

Fennec Pharmaceuticals Inc.

FENC M | $10.5 -3.05% -3.14% 100K

Health Technology

(0.0% 1d) (-1.5% 1m) (35.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-29.88% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 284,598,668
http://www.fennecpharma.com
Sec Filling | Patents | 4 employees

(US) Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

cancer msa

add to watch list Paper trade email alert is off

Focus Financial Partners Inc.

FOCS | $52.99 -0.02% -0.04% 6.8M

Finance

(0.0% 1d) (0.0% 1m) (2.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-17.3% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 3,498,318,407
http://www.focusfinancialpartners.com
Sec Filling | Patents | 3400 employees

(US) Focus Financial Partners, Inc. is a holding company, which engages in the provision of wealth management services. It also offers practices, resources, and continuity planning for its partner firms who serve individuals, families, employers, and institutions with comprehensive wealth management services. The company was founded by Leonard R. Chang, Ruediger Adolf and Rajini Sundar Kodialam on July 29, 2015 and is headquartered in New York, NY.

add to watch list Paper trade email alert is off

Franchise Group, Inc.

FRG | $29.88 0.1% 0.1% 0

Commercial Services

(0.0% 1d) (0.2% 1m) (5.5% 1y) (0.1% 2d) (0.7% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 1,051,520,855
http://www.franchisegrp.com
Sec Filling | Patents | 8038 employees

(US) Franchise Group, Inc. is a holding company, which engages in the provision of tax return preparation and related services and products. It operates through the United States Operations and Canadian Operations segments. It offers personal and business tax preparation services, facilitates refund-based tax settlement financial products, and online tax preparation services. The company was founded by Danny Hewitt and John T. Hewitt on September 1, 1997 and is headquartered in Virginia Beach, VA.

add to watch list Paper trade email alert is off

Genius Brands International, Inc.

GNUS 4 | $3.24 4.93% 760K

Consumer Services

(0.0% 1d) (0.0% 1m) (21.8% 1y) (8.4% 2d) (1.6% 3d) (0.0% 7d) (122.22% volume)
Earnings Calendar:
Market Cap: $ 104,060,544
http://www.gnusbrands.com
Sec Filling | Patents | 20 employees

(US) Genius Brands International, Inc. is a content and brand management company, which engages in developing, producing, marketing, and licensing branded children’s entertainment properties and consumer products for media distribution and retail channels. The firm acts as a licensing agent for certain brands, such as Llama Llama, Psycho Bunny, From Frank, and Celessence Technologies. The company was founded by Balaban Howard Alan on January 2, 2006 and is headquartered in Beverly Hills, CA.

brands msa

add to watch list Paper trade email alert is off

Genocea Biosciences, Inc.

GNCA | $0.051

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-15.0% 3d) (0.0% 7d) (-35.74% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.genocea.com
Sec Filling | Patents | 59 employees

(US) Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

vaccine cancer immunotherapy t-cell genetic treatment ceiling

add to watch list Paper trade email alert is off

Global Blood Therapeutics, Inc.

GBT | $68.49 0.02% -0.02%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (73.96% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 4,621,443,500
http://www.gbt.com
Sec Filling | Patents | 352 employees

(US) Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

t-cell ceiling

Drugs

OXBRYTA (Voxelotor)

add to watch list Paper trade email alert is off

Green Plains Partners LP

GPP 4 | $12.31 0.73% 260K

Transportation

(0.0% 1d) (0.0% 1m) (-7.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-66.87% volume)
Earnings Calendar:
Market Cap: $ 286,390,094
http://www.greenplainspartners.com
Sec Filling | Patents | 40 employees

(US) Green Plains Partners LP provides ethanol and fuel storage, terminal and transportation services by owning, operating, developing and acquiring ethanol and fuel storage tanks, terminals, transportation assets and other related assets and businesses. The company was founded on March 2, 2015 and is headquartered in Omaha, NE.

add to watch list Paper trade email alert is off

Greenrose Acquisition Corp.

GNRS 4 | $0.001 33900.0% 110K

Finance

(0.0% 1d) (0.0% 1m) (-99.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (0.88% volume)
Earnings Calendar:
Market Cap: $ 17,383
https://greenrosecorp.com
Sec Filling | Patents | 2020 employees

(US) Greenrose Acquisition Corp. operates as a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded on August 26, 2019 and is headquartered in Woodbury, N Y.

acquisitions msa blank check

add to watch list Paper trade email alert is off

Harbor Custom Development, Inc.

HCDI | $0.199 -24.47% 1.2M

Finance

(0.0% 1d) (0.0% 1m) (-94.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.35% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 463,535
http://harborcustomhomes.com
Sec Filling | Patents | 40 employees

(US) Harbor Custom Development, Inc. is an emerging growth company, which engages in the construction, sale, and management of residential properties. Its portfolio includes single-family lots, multi-family properties, and home communities. The company was founded by Sterling Griffin in February 2014 and is headquartered in Gig Harbor, WA.

construction

add to watch list Paper trade email alert is off

Harpoon Therapeutics, Inc.

HARP | $23.01 0.07% 6.6M

Health Technology

(0.0% 1d) (0.0% 1m) (3796.6% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (122.25% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 389,611,579
http://www.harpoontx.com
Sec Filling | Patents | 61 employees

(US) Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

cancer immunotherapy glass t-cell treatment ceiling construction

add to watch list Paper trade email alert is off

Hemisphere Media Group, Inc.

HMTV 4 | $7.15 1.56% -0.28%

Consumer Services

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-8.95% volume)
Earnings Calendar: 2022-11-03
Market Cap:
http://www.hemispheretv.com
Sec Filling | Patents | 330 employees

(US) Hemisphere Media Group, Inc. engages in the operation of networks and content production platform, which includes movie and telenovela channels. Its platforms include Cinelatino, WAPA, WAPA America, Pasiones, Centroamerica TV, and Television Dominicana. The company was founded on January 16, 2013 and is headquartered in Coral Gables, FL.

add to watch list Paper trade email alert is off

Heska Corporation

HSKA | $119.99 0.0% 390K

Health Technology

(0.0% 1d) (0.0% 1m) (2.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (87.26% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 1,309,541,342
http://www.heska.com
Sec Filling | Patents | 386 employees

(US) Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through two segments: Core Companion Animal Health and Other Vaccines & Pharmaceuticals. The Core Companion Animal Health segment includes point of care diagnostic laboratory instruments and supplies, imaging instruments, software, and services as well as single use diagnostic and other tests, pharmaceuticals, and vaccines. The Other Vaccines & Pharmaceuticals segment focuses on private label vaccine and pharmaceutical production, primarily for cattle, but also for equine, porcine, avian, feline, and canine. Heska was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.

vaccine animals diagnostics veterinary

add to watch list Paper trade email alert is off

9 Meters Biopharma, Inc.

NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

(0.0% 1d) (0.0% 1m) (-93.6% 1y) (0.0% 2d) (0.0% 3d) (-43.0% 7d) (254.86% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 1,043,990
http://www.innovatebiopharma.com
Sec Filling | Patents | 8 employees

(US) 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

autoimmunity

add to watch list Paper trade email alert is off

ABIOMED, Inc.

ABMD | $381.02 0.06% 0.07%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (758.37% volume)
Earnings Calendar: 2023-02-02
Market Cap: $ 17,180,642,928
http://www.abiomed.com
Sec Filling | Patents | 1536 employees

(US) ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.

heart brands

add to watch list Paper trade email alert is off

Abraxas Petroleum Corporation

AXAS 4 | $0.0347 1686.74% 690

Energy Minerals

(0.0% 1d) (0.0% 1m) (-94.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-89.64% volume)
Earnings Calendar:
Market Cap: $ 3,494,340
http://www.abraxaspetroleum.com
Sec Filling | Patents | 65 employees

(US) Abraxas Petroleum Corp. engages in the acquisition, exploration, development, and production of crude oil and natural gas. It focuses primarily on the development of conventional and unconventional resources in its primary operating areas in the Rocky Mountains, South Texas, Powder River Basin and Permian Basin. The company was founded by Robert L.G. Watson in 1977 and is headquartered in San Antonio, TX.

acquisitions natural gas crude oil urea

add to watch list Paper trade email alert is off

Acer Therapeutics Inc.

ACER | $0.9 -3.61% 420K

Health Technology

(0.0% 1d) (0.0% 1m) (1.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1077.06% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 22,017,353
http://www.acertx.com
Sec Filling | Patents | 17 employees

(US) Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.

acquisitions urine urea treatment

add to watch list Paper trade email alert is off

Adamis Pharmaceuticals Corporation

ADMP | $0.7751 0.86% 2.6% 120K

Health Technology

(0.0% 1d) (0.0% 1m) (-87.7% 1y) (0.0% 2d) (0.9% 3d) (0.0% 7d) (20.14% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 7,254,264
http://www.adamispharmaceuticals.com
Sec Filling | Patents | 171 employees

(US) Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.

respiratory opioid

add to watch list Paper trade email alert is off

Aerie Pharmaceuticals, Inc.

AERI | $15.25 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.48% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 753,615,457
http://www.aeriepharma.com
Sec Filling | Patents | 380 employees

(US) Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

eye treatment

Drugs

Rhopressa (netarsudil)
Rocklatan (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)

add to watch list Paper trade email alert is off

Bellicum Pharmaceuticals, Inc.

BLCM | $0.0748 381.28% 6.1K

Health Technology

(0.0% 1d) (0.0% 1m) (-77.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3229.12% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 726,826
http://www.bellicum.com
Sec Filling | Patents | 107 employees

(US) Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

cancer immunotherapy

add to watch list Paper trade email alert is off